ArticleSouth Asian journal of cancer2025
High-Grade Gastrointestinal Neuroendocrine Carcinomas: Multidisciplinary Approach Can Improve Survival Outcomes.
Article in South Asian journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Validity of NETest2.0Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: There is limited evidence for the presentation patterns and outcomes of patients with high-grade gastrointestinal neuroendocrine carcinomas (HG-NEC). Methods: Patients diagnosed with HG-NEC, defined as having a pathological diagnosis of neuroendocrine cancer with an epicenter of cancer in the gastrointestinal tract and Molecular Immunology Borstel-1 index ≥ 20% between May 2014 and May 2022 were retrospectively analyzed for demographic variables, survivals, and prognostic parameters. The primary endpoint of the study was the estimation of median overall survival (OS) by the Kaplan-Meier method. Results: A total of 336 patients were included in the analysis, of whom 283 patients (84%) were started on cancer-directed treatment while 53 patients (16%) were planned for best supportive care. The most common sites of the primary were gallbladder (45%), colorectal (19%), and pancreas (13%), with 253 patients (75%) having metastatic NEC. All treated patients received systemic therapy (commonly platinum and etoposide), while 64 patients (23%) underwent resection of the primary. With a median follow-up of 65.4 (45.6 -85.3) months, the median OS of the entire cohort was 15.8 months. The prospective multidisciplinary tumor (MDT) board decision of classifying patients into resectable, unresectable, and metastatic HG-NEC was prognostic for OS (26.8 vs. 21.1 vs. 13.5 months; Conclusion: A majority of patients with HG-NEC present with advanced disease. An MDT is essential to deciding initial therapeutic strategies in these patients, with patients undergoing resection and systemic therapy having improved OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.